Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Anticoagulation and heart failure.

S P Graham1

  • 1Buffalo General Hospital, Department of Medicine, Division of Cardiology, 100 High Street, Buffalo, NY 14203, USA. Dbrennan@KaleidaHealth.org

Current Cardiology Reports
|January 5, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Evaluation of electropolymerized molecularly imprinted polymers (E-MIPs) on disposable electrodes for detection of SARS-CoV-2 in saliva.

Analytica chimica acta·2022
Same author

The major histocompatibility complex homozygous inbred Babraham pig as a resource for veterinary and translational medicine.

HLA·2018
Same author

Pathology and Virus Distribution in the Lung and Lymphoid Tissues of Pigs Experimentally Inoculated with Three Distinct Type 1 PRRS Virus Isolates of Varying Pathogenicity.

Transboundary and emerging diseases·2014
Same author

Increased pathogenicity of European porcine reproductive and respiratory syndrome virus is associated with enhanced adaptive responses and viral clearance.

Veterinary microbiology·2013
Same author

Characterisation of experimental infections of domestic pigs with genotype 2.1 and 3.3 isolates of classical swine fever virus.

Veterinary microbiology·2009
Same author

Characterization of efferent lymph cells and their function following immunization of cattle with an allogenic Theileria annulata infected cell line.

Veterinary immunology and immunopathology·2003
Same journal

Cardioimmunology of Myocarditis: Targeting the IL-1 Pathway.

Current cardiology reports·2026
Same journal

Antithrombotic Management in Patients with Chronic Coronary Syndrome Receiving Oral Anticoagulation.

Current cardiology reports·2026
Same journal

Transcriptome Reprogramming in Heart Failure: The Hidden Splicing Code.

Current cardiology reports·2026
Same journal

Diagnosis and Management of Loeys-Dietz Syndrome: Evidence Gaps and Future Directions.

Current cardiology reports·2026
Same journal

Correction: Heart Disease in Older Women: Unique Challenges in Diagnosis and Management.

Current cardiology reports·2026
Same journal

Beyond the ICD: Navigating Ventricular Tachycardia Suppression Strategies in the Modern Era.

Current cardiology reports·2026
See all related articles

For patients with left ventricular systolic dysfunction, optimal antithrombotic therapy (warfarin or aspirin) remains unclear. Individualized treatment considering heart failure severity and renal function is crucial while awaiting further research.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Left ventricular systolic dysfunction (LVSD) management lacks clear guidelines for antithrombotic therapy.
  • Aspirin and warfarin are commonly considered, but their use in LVSD presents challenges.
  • Aspirin may impair renal blood flow in low-output states, and warfarin dosing is complex in advanced heart failure.

Purpose of the Study:

  • To review the current understanding of antithrombotic therapy in patients with LVSD.
  • To highlight the complexities and considerations for using warfarin and aspirin in this population.
  • To emphasize the need for individualized treatment strategies.

Main Methods:

  • Literature review and clinical expertise synthesis.
  • Analysis of drug effects on renal function and heart failure.

Related Experiment Videos

  • Discussion of warfarin dosing challenges in heart failure.

    • Main Results:

    • No definitive data supports warfarin, aspirin, or no therapy for LVSD.
    • Ejection fraction and symptom class may not correlate with thromboembolic risk.
    • Warfarin dosing regulation is difficult in worsening heart failure.

    Conclusions:

    • Individualized drug selection is essential, considering heart failure etiology, functional class, side effects, and renal function.
    • Ongoing studies are needed to clarify the differential effects of these drugs on outcomes.
    • Further research is required to understand the mechanisms of action and optimize therapy for LVSD patients.